Ascension Ventures is a venture capital firm that led the pre-seed funding round for Voxmind.
The round was led by Ascension through its Fair By Design Fund with backing from Fin Venture Capital and angel investors.
"We’re thrilled to have Ken join our board, his depth of experience and proven record of delivering strong growth across financial sector companies make him an excellent addition as we build our global delivery capability"
The London-based wearable technology startup raised the capital from backers including Chevron Technology Ventures and Vinci.
"Clear voice communication is particularly valuable in hazardous areas. Our trial of the Mobilus device helped us assess its potential to enhance worker safety, particularly in high-noise industrial environments,"
The London startup has raised 4m euro from backers including byFounders and Flash Ventures to grow its team and enter new markets.
"We have known and supported Fuzey from the very beginning and are very happy to continue supporting them. We are big believers in the team’s vision to empower small businesses with the digital tools they need. We have been impressed by the rapid traction and positive impact on their users’ businesses."
The seed round was led by Octopus Ventures to support platform growth and white-label expansion.
"I am absolutely convinced that the future of fashion is circular, and we are proud to be at the forefront of this accelerating consumer shift. In the UK alone, customers spend £2.7 billion on outfits they wear just once while more than $400 billion of clothing is discarded across the globe each year – another shocking statistic. As a millennial, I’m part of a generation that loves shared ownership. We’ve all witnessed the rise of disruptive tech-first businesses such as Airbnb and Uber and if we can rent our houses and cars, why not our wardrobes."
The financing round was led by Talis Capital with participation from multiple angels and existing backers.
"We are delighted to have received such credible investor support to continue on our mission to empower and support those with cancer. It’s imperative that we start understanding how therapies are affecting patients: for pharmaceutical companies, our technology enables deeper patient understanding which leads to better drugs, greater differentiation and faster licensing, as well as the ability to provide personalised scalable support to patients. For patients, this means better care and improved outcomes from cancer. We’re now looking forward to applying our rich data and machine learning capabilities to novel predictive analytics to generate even richer insights for our life science partners."
